Building on last year’s success, our CTS team have conducted extensive research to ensure the 2018 event programme covers all the essentials in clinical supply.
Backed by a $202 million fundraiser, biotech Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following a phase 3 trial success.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.